Novartis’ Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

August 25, 2020 Auto Bot Biotech, Clinical Trials, Fails, Meet, Novartis, P-III, Primary Endpoint, Study 0

Shots:

  • The P-III study involves assessing of spartalizumab (PDR001) + Tafinlar (dabrafenib) and Mekinist (trametinib) vs PBO + Tafinlar and Mekinist in previously untreated patients with unresectable or metastatic BRAF V600 mutation-positive melanoma
  • The study was conducted in three parts while today’s results are from part 3 of the trial. The study did not meet its 1EPS of investigator-assessed progression-free survival
  • Spartalizumab is mAb targeting PD-1 receptor while Tafinlar and Mekinist are prescription medicines, used in combination to prevent melanoma

Click here ­to­ read full press release/ article | Ref: Novartis | Image: CNBC